Dania is an Entrepreneur-in-Residence and an immunologist with nearly two decades of experience in drug discovery, translational research, and early clinical development in autoimmune and inflammatory diseases. Dania was previously Chief Scientific Officer at Rheos Medicines where she set scientific strategy, progressed precision medicine platform, and advanced lead asset to IND. Previously Dania was Head of the Drug Discovery Incubator, Research and Early Development at Biogen. She advanced candidates from program initiation through clinical development, notably litifilimab (anti-BDCA2 mAb) currently in phase 3 clinical development in CLE and SLE.Dania earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University/ Medical College of Virginia; and M.S. in Human Morphology and Immunology and B.S. in Biology from the American University of Beirut. She completed her post-doctoral training in Immunology at Harvard Medical School.